A Retrospective Study of Immunotherapy in Conversion Therapy of

Clinical Trial Summary

This study was an observational, non-interventional, multicenter retrospective study to evaluate the feasibility and safety of sintilimab combined with chemotherapy (SOX or PS) in the clinical practice of unresectable locally advanced or stage IV gastric cancer/gastroesophageal junction carcinoma.

See also
	Status	Clinical Trial	Phase
	Recruiting	`NCT03822130` - Intra-arterial Infusion Chemotherapy Combined With Sodium Bicarbonate for Unresectable Gastric Cancer	Early Phase 1

See also

Status

Clinical Trial

Phase

Recruiting

NCT03822130 - Intra-arterial Infusion Chemotherapy Combined With Sodium Bicarbonate for Unresectable Gastric Cancer

Early Phase 1

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT05385809
Study type	Observational
Source	Zhejiang Cancer Hospital
Contact	Pengfei Yu, MD, PhD
Phone	86-571-88128031
Email	ypfzmu@163.com
Status	Recruiting
Phase
Start date	June 1, 2022
Completion date	December 31, 2023

A Retrospective Study of Immunotherapy in Conversion Therapy of Unresectable Gastric Cancer

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms